The $120 billion question: Is India ready to take lead in pharma manufacturing space?

India's pharmaceutical industry stands at a defining moment. With global supply chains undergoing significant transformation and the "China+1" strategy gaining momentum, the country has an unprecedented opportunity to strengthen its position as a global pharmaceutical manufacturing powerhouse.

As India's pharma market is projected to grow to USD 120–130 billion by 2030, the industry's success will depend on more than market size. Building resilient API supply chains, strengthening regulatory compliance, investing in infrastructure and talent, and expanding into high-value segments such as biosimilars and CRDMO will be critical to sustaining long-term growth.

This article examines the opportunities, challenges, and strategic priorities that will determine whether India can translate its manufacturing strengths into lasting global leadership.

Key takeaways

• India's pharmaceutical market is expected to more than double by 2030.
• The "China+1" strategy presents a significant opportunity for Indian manufacturers.
• Reducing dependence on imported APIs and KSMs remains a strategic priority.
• Continued improvements in quality, compliance, and regulatory standards are essential for global competitiveness.
• Investments in pharma parks, research, innovation, and skilled talent will shape the industry's next phase of growth.

Read the full article to explore how India can capitalise on this pivotal opportunity and what lies ahead for the country's pharmaceutical manufacturing ecosystem.